LMAT
LeMaitre Vascular, Inc.
Price Chart
Latest Quote
$93.31
+1.06 (+1.14%)
Current Price
| Previous Close | $92.25 |
| Open | $92.91 |
| Day High | $94.00 |
| Day Low | $92.39 |
| Volume | 14,688 |
Stock Information
| Quarterly Dividend / Yield | $1.00 / 1.08% |
| Shares Outstanding | 22.85M |
| Quarterly Dividend Yield | 1.08% |
| Quarterly Dividend | $1.00 |
| Total Debt | $189.82M |
| Cash Equivalents | $367.23M |
| Revenue | $256.28M |
| Net Income | $62.40M |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Market Cap | $2.13B |
| P/E Ratio | 34.30 |
| EPS (TTM) | $2.72 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.93B |
| Sales | $256.28M |
| Income | $62.40M |
| Book/sh | $17.80 |
| Cash/sh | $16.07 |
| Employees | 646 |
Financial Ratios
| Quick Ratio | 12.08 |
| Current Ratio | 14.32 |
| Debt/Eq | 46.68 |
| EPS Growth TTM | 42.40% |
Returns & Margins
| ROA | 7.20% |
| ROE | 16.55% |
| Gross Margin | 71.33% |
| Operating Margin | 26.71% |
| Profit Margin | 24.35% |
Ownership
| Insider Ownership | 6.51% |
| Institutional Ownership | 100.38% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 28.66 |
| PEG | 2.56 |
| P/S | 8.32 |
| P/B | 5.24 |
Analyst Data
| Recommendation | none |
| Target Price | $118.75 |
Technical Indicators
| SMA20 | $92.89 |
| SMA50 | $101.05 |
| SMA200 | $93.82 |
| RSI | 49.42 |
| ATR | 2.9107 |
| Shares Float | 21.27M |
| Short Float | 6.54% |
| Short Ratio | 3.87 |
| Volatility | 0.52 |
| Rel Volume | 0.05 |
Performance History
| Week | +1.19% |
| Month | -5.48% |
| Quarter | -15.79% |
| 6 Months | +10.94% |
| YTD | +16.94% |
| Year | +11.04% |
| 3 Years | +41.28% |
| 5 Years | +59.90% |
| 10 Years | +638.96% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $93.31 | 14,688 |
| 2026-06-24 | $92.25 | 225,700 |
| 2026-06-23 | $91.95 | 441,800 |
| 2026-06-22 | $88.61 | 401,500 |
| 2026-06-18 | $93.95 | 724,900 |
| 2026-06-17 | $92.21 | 257,900 |
| 2026-06-16 | $93.39 | 195,800 |
| 2026-06-15 | $91.92 | 213,100 |
| 2026-06-12 | $91.96 | 212,400 |
| 2026-06-11 | $92.34 | 558,200 |
| 2026-06-10 | $92.34 | 284,100 |
| 2026-06-09 | $96.59 | 444,800 |
| 2026-06-08 | $95.11 | 244,100 |
| 2026-06-05 | $94.48 | 244,100 |
| 2026-06-04 | $93.56 | 310,000 |
| 2026-06-03 | $91.64 | 212,600 |
| 2026-06-02 | $91.62 | 273,300 |
| 2026-06-01 | $91.42 | 246,400 |
| 2026-05-29 | $94.65 | 516,100 |
| 2026-05-28 | $94.54 | 220,600 |
| 2026-05-27 | $95.72 | 213,000 |
| 2026-05-26 | $98.71 | 503,800 |
About LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
đ° Latest News
3 of Wall Streetâs Favorite Stocks We Find Risky
StockStory âĸ 2026-06-02T12:37:23Z
How The LeMaitre Vascular (LMAT) Story Is Shifting As Analysts Lift Fair Value Targets
Simply Wall St. âĸ 2026-05-29T05:02:58Z
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
Zacks âĸ 2026-05-25T16:45:02Z
1 Reason to Avoid LMAT and 1 Stock to Buy Instead
StockStory âĸ 2026-05-22T23:40:55Z
Winners And Losers Of Q1: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
StockStory âĸ 2026-05-21T01:08:55Z
3 Healthcare Stocks with Open Questions
StockStory âĸ 2026-05-18T09:40:55Z
5 Insightful Analyst Questions From LeMaitreâs Q1 Earnings Call
StockStory âĸ 2026-05-15T04:44:55Z
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
Zacks âĸ 2026-05-13T13:35:03Z
US$118 - That's What Analysts Think LeMaitre Vascular, Inc. (NASDAQ:LMAT) Is Worth After These Results
Simply Wall St. âĸ 2026-05-07T18:47:24Z
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
Zacks âĸ 2026-05-07T16:45:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $71,063,000 | $68,962,000 | $66,435,000 | $56,755,000 |
| Cost Of Revenue | $71,063,000 | $68,962,000 | $66,435,000 | $56,755,000 |
| Total Revenue | $249,602,000 | $219,863,000 | $193,484,000 | $161,651,000 |
| Operating Revenue | $249,602,000 | $219,863,000 | $193,484,000 | $161,651,000 |
| Expenses | ||||
| Interest Expense | $5,184,000 | $205,000 | $0 | $0 |
| Total Expenses | $181,690,000 | $167,607,000 | $156,287,000 | $131,715,000 |
| Other Income Expense | $12,456,000 | $4,824,000 | $2,278,000 | $-3,432,000 |
| Other Non Operating Income Expenses | $-638,000 | $-125,000 | $-314,000 | $-325,000 |
| Net Non Operating Interest Income Expense | $-5,184,000 | $-205,000 | $0 | $986,000 |
| Interest Expense Non Operating | $5,184,000 | $205,000 | $0 | $0 |
| Operating Expense | $110,627,000 | $98,645,000 | $89,852,000 | $74,960,000 |
| Selling And Marketing Expense | $54,464,000 | $46,737,000 | $41,054,000 | $32,921,000 |
| General And Administrative Expense | $42,024,000 | $36,258,000 | $31,832,000 | $28,745,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $57,734,000 | $44,038,000 | $30,105,000 | $20,636,000 |
| Net Interest Income | $-5,184,000 | $-205,000 | $0 | $986,000 |
| Normalized Income | $47,677,808 | $40,207,474 | $28,127,304 | $22,969,357 |
| Net Income From Continuing And Discontinued Operation | $57,734,000 | $44,038,000 | $30,105,000 | $20,636,000 |
| Total Operating Income As Reported | $67,912,000 | $52,256,000 | $36,712,000 | $26,829,000 |
| Net Income Common Stockholders | $57,734,000 | $44,038,000 | $30,105,000 | $20,636,000 |
| Net Income | $57,734,000 | $44,038,000 | $30,105,000 | $20,636,000 |
| Net Income Including Noncontrolling Interests | $57,734,000 | $44,038,000 | $30,105,000 | $20,636,000 |
| Net Income Continuous Operations | $57,734,000 | $44,038,000 | $30,105,000 | $20,636,000 |
| Pretax Income | $75,184,000 | $56,875,000 | $39,475,000 | $27,490,000 |
| Special Income Charges | $0 | $0 | $-485,000 | $-3,107,000 |
| Operating Income | $67,912,000 | $52,256,000 | $37,197,000 | $29,936,000 |
| Gross Profit | $178,539,000 | $150,901,000 | $127,049,000 | $104,896,000 |
| Interest Income | - | $4,949,000 | $3,077,000 | $986,000 |
| Interest Income Non Operating | - | $4,949,000 | $3,077,000 | $986,000 |
| Per Share | ||||
| Diluted EPS | $2.52 | $1.93 | $1.34 | $0.93 |
| Basic EPS | $2.55 | $1.96 | $1.36 | $0.94 |
| Other | ||||
| Tax Effect Of Unusual Items | $3,037,808 | $1,118,474 | $614,304 | $-773,643 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $77,692,000 | $61,739,000 | $46,398,000 | $40,030,000 |
| Total Unusual Items | $13,094,000 | $4,949,000 | $2,592,000 | $-3,107,000 |
| Total Unusual Items Excluding Goodwill | $13,094,000 | $4,949,000 | $2,592,000 | $-3,107,000 |
| Reconciled Depreciation | $10,418,000 | $9,608,000 | $9,515,000 | $9,433,000 |
| EBITDA (Bullshit earnings) | $90,786,000 | $66,688,000 | $48,990,000 | $36,923,000 |
| EBIT | $80,368,000 | $57,080,000 | $39,475,000 | $27,490,000 |
| Diluted Average Shares | $22,929,000 | $22,779,000 | $22,423,000 | $22,171,000 |
| Basic Average Shares | $22,638,000 | $22,452,000 | $22,217,000 | $21,975,000 |
| Diluted NI Availto Com Stockholders | $57,734,000 | $44,038,000 | $30,105,000 | $20,636,000 |
| Tax Provision | $17,450,000 | $12,837,000 | $9,370,000 | $6,854,000 |
| Restructuring And Mergern Acquisition | $0 | $0 | $485,000 | $3,107,000 |
| Gain On Sale Of Security | $13,094,000 | $4,949,000 | $3,077,000 | - |
| Research And Development | $14,139,000 | $15,650,000 | $16,966,000 | $13,294,000 |
| Selling General And Administration | $96,488,000 | $82,995,000 | $72,886,000 | $61,666,000 |
| Other Gand A | $42,024,000 | $36,258,000 | $31,832,000 | $28,745,000 |
| Gain On Sale Of Ppe | - | - | - | $0 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $294,482,000 | $235,526,000 | $190,244,000 | $155,729,000 |
| Total Assets | $615,690,000 | $551,817,000 | $346,778,000 | $310,476,000 |
| Total Non Current Assets | $147,458,000 | $149,625,000 | $152,180,000 | $148,743,000 |
| Other Non Current Assets | $4,906,000 | $4,868,000 | $3,740,000 | $991,000 |
| Non Current Deferred Assets | $759,000 | $1,425,000 | $1,003,000 | $1,745,000 |
| Non Current Deferred Taxes Assets | $759,000 | $1,425,000 | $1,003,000 | $1,745,000 |
| Goodwill And Other Intangible Assets | $99,034,000 | $101,764,000 | $107,656,000 | $112,472,000 |
| Other Intangible Assets | $33,089,000 | $35,819,000 | $41,711,000 | $46,527,000 |
| Current Assets | $468,232,000 | $402,192,000 | $194,598,000 | $161,733,000 |
| Other Current Assets | $5,080,000 | $7,480,000 | $6,380,000 | $6,731,000 |
| Current Deferred Assets | $12,176,000 | $8,985,000 | $5,747,000 | $4,992,000 |
| Inventory | $58,246,000 | $55,942,000 | $52,333,000 | $45,279,000 |
| Receivables | $33,610,000 | $30,063,000 | $25,064,000 | $22,040,000 |
| Accounts Receivable | $33,610,000 | $30,063,000 | $25,064,000 | $22,040,000 |
| Allowance For Doubtful Accounts Receivable | $-1,400,000 | $-1,369,000 | $-941,000 | $-835,000 |
| Gross Accounts Receivable | $35,010,000 | $31,432,000 | $26,005,000 | $22,875,000 |
| Cash Cash Equivalents And Short Term Investments | $359,120,000 | $299,722,000 | $105,074,000 | $82,691,000 |
| Cash And Cash Equivalents | $28,244,000 | $25,610,000 | $24,269,000 | $19,134,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $140,401,000 | $142,162,000 | - | - |
| Total Debt | $185,592,000 | $185,685,000 | $19,095,000 | $16,596,000 |
| Long Term Debt And Capital Lease Obligation | $182,648,000 | $183,004,000 | $16,624,000 | $14,710,000 |
| Long Term Debt | $168,645,000 | $167,772,000 | - | - |
| Current Debt And Capital Lease Obligation | $2,944,000 | $2,681,000 | $2,471,000 | $1,886,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $222,174,000 | $214,527,000 | $48,878,000 | $42,275,000 |
| Total Non Current Liabilities Net Minority Interest | $185,851,000 | $183,920,000 | $18,999,000 | $16,946,000 |
| Other Non Current Liabilities | $964,000 | $259,000 | $1,631,000 | $1,531,000 |
| Tradeand Other Payables Non Current | $504,000 | $572,000 | $637,000 | $636,000 |
| Non Current Deferred Liabilities | $1,735,000 | $85,000 | $107,000 | $69,000 |
| Non Current Deferred Taxes Liabilities | $1,735,000 | $85,000 | $107,000 | $69,000 |
| Current Liabilities | $36,323,000 | $30,607,000 | $29,879,000 | $25,329,000 |
| Other Current Liabilities | $322,000 | $1,433,000 | $24,000 | $573,000 |
| Payables And Accrued Expenses | $33,057,000 | $26,493,000 | $27,384,000 | $22,870,000 |
| Interest Payable | $1,797,000 | $144,000 | $0 | - |
| Payables | $23,593,000 | $17,517,000 | $17,477,000 | $14,122,000 |
| Total Tax Payable | $19,947,000 | $15,756,000 | $13,743,000 | $11,219,000 |
| Income Tax Payable | $1,661,000 | $639,000 | $390,000 | $449,000 |
| Accounts Payable | $3,646,000 | $1,761,000 | $3,734,000 | $2,903,000 |
| Equity | ||||
| Common Stock Equity | $393,516,000 | $337,290,000 | $297,900,000 | $268,201,000 |
| Total Equity Gross Minority Interest | $393,516,000 | $337,290,000 | $297,900,000 | $268,201,000 |
| Stockholders Equity | $393,516,000 | $337,290,000 | $297,900,000 | $268,201,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,411,000 | $-6,184,000 | $-4,625,000 | $-6,031,000 |
| Other Equity Adjustments | $-2,411,000 | $-6,184,000 | $-4,625,000 | $-6,031,000 |
| Retained Earnings | $184,715,000 | $145,090,000 | $115,430,000 | $97,773,000 |
| Other | ||||
| Treasury Shares Number | $1,624,297 | $1,603,825 | $1,584,512 | $1,568,595 |
| Ordinary Shares Number | $22,772,607 | $22,549,340 | $22,327,248 | $22,087,121 |
| Share Issued | $24,396,904 | $24,153,165 | $23,911,760 | $23,655,716 |
| Tangible Book Value | $294,482,000 | $235,526,000 | $190,244,000 | $155,729,000 |
| Invested Capital | $562,161,000 | $505,062,000 | $297,900,000 | $268,201,000 |
| Working Capital | $431,909,000 | $371,585,000 | $164,719,000 | $136,404,000 |
| Capital Lease Obligations | $16,947,000 | $17,913,000 | $19,095,000 | $16,596,000 |
| Total Capitalization | $562,161,000 | $505,062,000 | $297,900,000 | $268,201,000 |
| Treasury Stock | $17,439,000 | $15,618,000 | $13,899,000 | $13,046,000 |
| Additional Paid In Capital | $228,407,000 | $213,760,000 | $200,755,000 | $189,268,000 |
| Capital Stock | $244,000 | $242,000 | $239,000 | $237,000 |
| Common Stock | $244,000 | $242,000 | $239,000 | $237,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $14,003,000 | $15,232,000 | $16,624,000 | $14,710,000 |
| Current Capital Lease Obligation | $2,944,000 | $2,681,000 | $2,471,000 | $1,886,000 |
| Current Accrued Expenses | $9,464,000 | $8,976,000 | $9,907,000 | $8,748,000 |
| Goodwill | $65,945,000 | $65,945,000 | $65,945,000 | $65,945,000 |
| Net PPE | $42,759,000 | $41,568,000 | $39,781,000 | $33,535,000 |
| Accumulated Depreciation | $-28,397,000 | $-24,216,000 | $-21,488,000 | $-25,124,000 |
| Gross PPE | $71,156,000 | $65,784,000 | $61,269,000 | $58,659,000 |
| Other Properties | $15,762,000 | $16,768,000 | $18,027,000 | $15,634,000 |
| Machinery Furniture Equipment | $29,241,000 | $23,763,000 | $22,261,000 | $27,793,000 |
| Properties | $26,153,000 | $25,253,000 | $20,981,000 | $15,232,000 |
| Finished Goods | $34,432,000 | $34,676,000 | $31,131,000 | $26,688,000 |
| Work In Process | $2,922,000 | $2,157,000 | $2,869,000 | $3,662,000 |
| Raw Materials | $20,892,000 | $19,109,000 | $18,333,000 | $14,929,000 |
| Other Short Term Investments | $330,876,000 | $274,112,000 | $80,805,000 | $63,557,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $10,770,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $74,468,000 | $37,162,000 | $29,486,000 | $22,149,000 |
| Operating Activities | ||||
| Operating Cash Flow | $81,251,000 | $44,124,000 | $36,751,000 | $25,378,000 |
| Cash Flow From Continuing Operating Activities | $81,251,000 | $44,124,000 | $36,751,000 | $25,378,000 |
| Operating Gains Losses | $-176,000 | $362,000 | $-220,000 | $1,619,000 |
| Investing Activities | ||||
| Capital Expenditure | $-6,783,000 | $-6,962,000 | $-7,265,000 | $-3,229,000 |
| Investing Cash Flow | $-64,941,000 | $-200,120,000 | $-24,715,000 | $-10,371,000 |
| Cash Flow From Continuing Investing Activities | $-64,941,000 | $-200,120,000 | $-24,715,000 | $-10,371,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-14,540,000 | $158,102,000 | $-7,131,000 | $-9,234,000 |
| Cash Flow From Continuing Financing Activities | $-14,540,000 | $158,102,000 | $-7,131,000 | $-9,234,000 |
| Net Other Financing Charges | $-1,433,000 | $-1,507,000 | - | $-1,070,000 |
| Cash Dividends Paid | $-18,109,000 | $-14,378,000 | $-12,448,000 | $-10,988,000 |
| Common Stock Dividend Paid | $-18,109,000 | $-14,378,000 | $-12,448,000 | $-10,988,000 |
| Issuance Of Capital Stock | - | $6,440,000 | $6,170,000 | $3,466,000 |
| Net Common Stock Issuance | - | $6,440,000 | $6,170,000 | $3,466,000 |
| Common Stock Issuance | - | $6,440,000 | $6,170,000 | $3,466,000 |
| Repurchase Of Capital Stock | - | - | - | $-642,000 |
| Other | ||||
| Issuance Of Debt | $0 | $169,266,000 | $0 | $0 |
| Income Tax Paid Supplemental Data | $13,439,000 | $12,837,000 | $7,549,000 | $8,343,000 |
| End Cash Position | $28,244,000 | $25,610,000 | $24,269,000 | $19,134,000 |
| Beginning Cash Position | $25,610,000 | $24,269,000 | $19,134,000 | $13,855,000 |
| Effect Of Exchange Rate Changes | $864,000 | $-765,000 | $230,000 | $-494,000 |
| Changes In Cash | $1,770,000 | $2,106,000 | $4,905,000 | $5,773,000 |
| Proceeds From Stock Option Exercised | $5,002,000 | $4,721,000 | $5,317,000 | $-642,000 |
| Net Issuance Payments Of Debt | $0 | $169,266,000 | $0 | $0 |
| Net Long Term Debt Issuance | $0 | $169,266,000 | $0 | $0 |
| Long Term Debt Issuance | $0 | $169,266,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-56,259,000 | $-193,158,000 | $-16,551,000 | $-8,000,000 |
| Sale Of Investment | $585,070,000 | $84,780,000 | $0 | $0 |
| Purchase Of Investment | $-641,329,000 | $-277,938,000 | $-16,551,000 | $-8,000,000 |
| Net Business Purchase And Sale | $-1,899,000 | $0 | $-899,000 | $0 |
| Purchase Of Business | $-1,899,000 | $0 | $-899,000 | $0 |
| Net PPE Purchase And Sale | $-6,783,000 | $-6,962,000 | $-7,265,000 | $-2,371,000 |
| Purchase Of PPE | $-6,783,000 | $-6,962,000 | $-7,265,000 | $-3,229,000 |
| Change In Working Capital | $-1,749,000 | $-20,102,000 | $-11,254,000 | $-13,402,000 |
| Change In Payables And Accrued Expense | $5,995,000 | $-779,000 | $4,599,000 | $645,000 |
| Change In Accrued Expense | $1,797,000 | $144,000 | $0 | - |
| Change In Interest Payable | $1,797,000 | $144,000 | $0 | - |
| Change In Payable | $4,198,000 | $-923,000 | $4,599,000 | $645,000 |
| Change In Account Payable | $4,198,000 | $-923,000 | $4,599,000 | $645,000 |
| Change In Prepaid Assets | $2,426,000 | $-2,331,000 | $-2,924,000 | $-3,096,000 |
| Change In Inventory | $-7,223,000 | $-10,574,000 | $-9,794,000 | $-7,418,000 |
| Change In Receivables | $-2,947,000 | $-6,418,000 | $-3,135,000 | $-3,533,000 |
| Changes In Account Receivables | $-2,947,000 | $-6,418,000 | $-3,135,000 | $-3,533,000 |
| Other Non Cash Items | $873,000 | $196,000 | $-78,000 | $-108,000 |
| Stock Based Compensation | $7,826,000 | $6,568,000 | $5,319,000 | $4,173,000 |
| Unrealized Gain Loss On Investment Securities | $535,000 | $0 | $0 | - |
| Provisionand Write Offof Assets | $817,000 | $813,000 | $344,000 | $637,000 |
| Asset Impairment Charge | $2,661,000 | $3,092,000 | $2,237,000 | $2,572,000 |
| Deferred Tax | $2,312,000 | $-451,000 | $783,000 | $-182,000 |
| Deferred Income Tax | $2,312,000 | $-451,000 | $783,000 | $-182,000 |
| Depreciation Amortization Depletion | $10,418,000 | $9,608,000 | $9,515,000 | $9,433,000 |
| Depreciation And Amortization | $10,418,000 | $9,608,000 | $9,515,000 | $9,433,000 |
| Net Foreign Currency Exchange Gain Loss | $-176,000 | $362,000 | $-705,000 | $-315,000 |
| Gain Loss On Sale Of Business | $0 | $0 | $485,000 | $1,954,000 |
| Net Income From Continuing Operations | $57,734,000 | $44,038,000 | $30,105,000 | $20,636,000 |
| Sale Of PPE | - | $0 | $0 | $858,000 |
| Gain Loss On Sale Of PPE | - | $0 | $0 | $-20,000 |
| Repayment Of Debt | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $0 | $0 |
| Common Stock Payments | - | - | - | $-642,000 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-23